News | June 12, 2022
Cantourage and Clever leaves intensify partnership for distribution of medical cannabis in Germany
Cantourage introduces second Clever Leaves medical cannabis product to the German market
Cantourage introduces second Clever Leaves medical cannabis product to the German market
Tislelizumab is now approved in nine indications in China
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
Centre of Excellence at Kharel comprises Skill-building Centre and Primary, Secondary and Higher Secondary schools
New Director supports NASDAQ rule on diversity
Sam Samad will be departing Illumina on July 8, 2022, after serving as CFO for more than five years.
Company hires life science veteran Jessica Cao to join management team
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
Subscribe To Our Newsletter & Stay Updated
